Explore the Agenda
Programme includes the topics designed to advance healthcare priorities and outcomes through innovation.
Speakers at DIA Europe 2021 Conference
You won't want to miss this line-up of speakers!
300+ speakers from the Regulatory Authorities, the European Commission, Industry, Academia, HTAs, Patient Organisations and more! Meet some of them below.
Jo De Cock, CEO, National Institute of Health and Disability Insurance
Jo De Cock is CEO of the National Institute of Health and Disability Insurance (NIHDI) since 1995. He has obtained a master of law and a master of criminology from the Catholic University of Louvain, where he started his professional experience. He continued his career by joining the Center for political, economical and social studies where he was researcher and political advisor.
Emer Cooke, Executive Director, European Medicines Agency (EMA)
Emer Cooke was nominated as Executive Director with a renewable five-year mandate by the Agency’s Management Board on 25 June 2020 and is the first woman at the helm of EMA. Ms. Cooke obtained her degree in pharmacy from Trinity College in Dublin, Ireland. She has additional Masters degrees in Science and Business Admin., also from Trinity.
Marco Greco, President, European Patients’ Forum
Marco Greco is president of the European Patients’ Forum since 2014. He has been Chairman of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) from 2008 to 2014. He has also been the founder of the EFCCA Youth Group, and its leader from 2003 till 2007. He is patients’ representative, appointed by the European Commission in the Pharmacovigilance Risk Assessment Committee at the European Medicines Agency (EMA) and a member of the EMA Patients and Consumers Working Party (PCWP). He holds a degree in law from UCSC MILAN and a Ph. D. In Law and Religious freedom. He is actually working as attorney in his law firm.
Esteban Herrero-Martinez, Director Regulatory Policy and Intelligence, Abbvie Ltd
Previously Director of Regulatory Intelligence and Policy at Daiichi Sankyo Development Ltd, lead for Pharmacovigilance & Regulatory Affairs at the Association of the British Pharmaceutical Industry (ABPI) and Pharmacovigilance Manager at P&G Pharmaceuticals. Education: Biochemistry BSc from Warwick University, Virology PhD from University College London, Virology postdoc at Imperial College London.
François Houyez, Treatment Information and Access Director, Health Policy Advisor, European Organisation for Rare Diseases
François Houÿez is working at the European Organisation for Rare Diseases EURORDIS where he is Director of Treatment Information and Access, Policy Advisor. He represents EURORDIS at the Patients’ and Consumers’ Working Party at the European Medicines Agency (EMA) where he is the topic leader for Pharmacovigilance.
Anthony Humphreys, Head of Scientific Committees Regulatory Science Strategy, European Medicines Agency (EMA)
Anthony Humphreys is the Head of Scientific Committees Regulatory Science Strategy Division (SciRS). He is responsible for providing leadership in the Agency in the areas of Scientific Committees Coordination and Regulatory Science Strategy in support of delivering the EMRN 2020 Strategy. He chairs the Scientific Committee Coordination Board.
Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
Nathalie Moll is Director General at the European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
Alan Morrison, Vice President Regulatory Affairs Intl, Merck Sharp & Dohme
Alan leads the MSD international regulatory organization across EMEA, Canada, Latin America, and the Asia Pacific. He is a part of the Global Regulatory Affairs & Clinical Safety leadership team, also working with international cross-divisional leaders from across the business on the overall strategy and direction of the ex-US business & organization.
Stephan Roenninger, Director, Quality External Affairs ,Amgen (Europe) GmbH
Stephan Rönninger holds a PhD-engineering degree in organic chemistry from the TU Darmstadt, Germany, and was appointed as Adjunct Assistant Professor at GWU, Washington D.C.. He is in the Quality External Affairs organization in Amgen organizing the operational policy outreach and external ambassador program. He collaborates cross-functional internally and with external stakeholders including authorities, associations and competitors on topics regarding quality management, and good manufacturing and distribution practice (GMDP) as well as CMC topics by providing comments on regulatory guidelines, intelligence, and training.
Andrzej Rys, Director of Health Systems and Products, European Commission
Andrzej Rys is a medical Doctor (radiology and public health) who graduated from Jagiellonian University (JU) in Krakow, Poland. In 2006 he joined the European Commission as Public Health and Risk Assessment Director, DG for Health and Consumers. In 2011 he was appointed as Health Systems and Products Director, DG for Health and Consumers.
Thomas Senderovitz, Director General, Danish Medicines Agency
Thomas Senderovitz took over as Director General of the Danish Medicines Agency on 1 April 2016. His career includes more than 20 years working with medicinal products and he has held several senior positions in international biopharmaceutical Companies. He previously worked at the Clinical Pharmacological Department at Bispebjerg Hospital, Copenhagen. Thomas is Chair of HMA/EMA Joint Task Force on Big Data, member of the HMA Management Group and member of the EU Telematics Management Group. He is member of the Steering Committee for Copenhagen Center for Regulatory Science, member of the Reference Group for Crown Prince Frederik centre for Public Leadership and member of Dataetisk Råd.
Head of Unit B5 – Medicines: policy, authorisation and monitoring, DG SANTE, European Commission
Olga Solomon studied Chemistry at the Aristotle University of Thessaloniki, Greece and holds an MSc in Food Science from the Gothenburg University, Sweden. Before joining the European Commission she worked for 5 years for a beverage producing company in Greece. Solomon joined DG SANCO in 2000 and worked for 10 years in the field of Food Safety in particular dealing with legislation on Food Contact Materials, Food Additives and Enzymes. In 2010, she moved to the Directorate 'Health Systems and Products' where she worked in the field of substances of human origin before taking up a post in the pharmaceutical sector in 2011. She is currently the Head of the DG SANTE Unit responsible for Medicines: policy, authorisation and monitoring.
Rebecca Stanbrook, Global Head, quality regulatory Strategy, Novartis
Responsible for the GXP operational compliance program activities & initiatives. Prior to Novartis, she was Group Manager, Inspections (GLP/GCP/PV) at the MHRA. Since she joined the Agency in 2003, Rebecca held a number of positions within the fields of GCP and Pharmacovigilance; helped shape the GCP & PV statutory programmes in their early stages & was a member of one of the teams conducting the first statutory GCP inspections in the UK. Rebecca’s group at the Agency wrote the Good Clinical Practice Guide and the Good Pharmacovigilance Guide. She is also looking forward to participating in the working group for the ICH E6 R3 renovation.
Fergus Sweeney, Head of Inspections and Human Medicines Pharmacovigilance Division, European Medicines Agency (EMA)
Fergus Sweeney holds a PhD degree in Pharmacology from the University College Dublin and has held various positions at the EMA since 1999. Fergus Sweeney is the Head of Inspections, Human Medicines Pharmacovigilance and Committees at the European Medicines Agency since 2016.
Go back to top